Literature DB >> 8013962

Deficient T-cell responses in non-responders to hepatitis B vaccination: absence of TH1 cytokine production.

J Vingerhoets1, G Vanham, L Kestens, G Penne, G Leroux-Roels, P Gigase.   

Abstract

The inability to mount a protective level (> or = 10 IU/l) of hepatitis B surface antigen (HBsAg)-specific antibodies after vaccination is presumably the consequence of a defect in the cellular immune regulation. We compared the in vitro immune responses of peripheral blood mononuclear cells (PBMC) from high, intermediate and non-responders, after stimulation with recombinant HBsAg. The absence of a proliferative response in non-responders was not reversed by removal of CD8+ T cells, indicating that HBsAg-specific CD8+ T-cell-induced suppression was not the underlying cause of non-responsiveness. Non-responders did not produce cytokines after HBsAg stimulation. High responders displayed a typical Th1-like profile since their PBMC produced interleukin-2 (IL-2) and gamma-interferon (IFN gamma) and no detectable IL-4 or IL-5 upon stimulation with HBsAg.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8013962     DOI: 10.1016/0165-2478(94)90102-3

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  11 in total

1.  Characterization of the T cell recognition of hepatitis B surface antigen (HBsAg) by good and poor responders to hepatitis B vaccines.

Authors:  I Desombere; Y Gijbels; A Verwulgen; G Leroux-Roels
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

2.  The antibody response to HBs antigen is regulated by coordinated Th1 and Th2 cytokine production in healthy neonates.

Authors:  A Jafarzadeh; F Shokri
Journal:  Clin Exp Immunol       Date:  2003-03       Impact factor: 4.330

3.  Relationship between T-lymphocyte cytokine levels and sero-response to hepatitis B vaccines.

Authors:  Vijayakumar Velu; Shanmugam Saravanan; Subhadra Nandakumar; Esaki-Muthu Shankar; Appasamy Vengatesan; Suresh-Sakharam Jadhav; Prasad-Suryakant Kulkarni; Sadras-Panchatcharam Thyagarajan
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

4.  T cell responses to hepatitis B surface antigen are detectable in non-vaccinated individuals.

Authors:  Martin R Weihrauch; Michael von Bergwelt-Baildon; Milos Kandic; Martin Weskott; Winfried Klamp; Joachim Rosler; Joachim L Schultze
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

Review 5.  Drug delivery issues in vaccine development.

Authors:  M F Powell
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

Review 6.  Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases.

Authors:  D R Lucey; M Clerici; G M Shearer
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

7.  Enumeration of hepatitis B surface antigen-specific B lymphocytes in responder and non-responder normal individuals vaccinated with recombinant hepatitis B surface antigen.

Authors:  M A Shokrgozar; F Shokri
Journal:  Immunology       Date:  2001-09       Impact factor: 7.397

8.  Influence of some immune factors on the IL-6 and soluble IL-2 receptors in haemodialysed patients.

Authors:  M Kozioł-Montewka; A Ksiazek; M Majdan; D Spasiewicz; L Brydak; L Janicka; S Toś-Luty; J Sitkowska; C Skórska; J Latoszyńska; E Przylepa
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

9.  A Prospective Study of Humoral and Cellular Immune Responses to Hepatitis B Vaccination in Habitual Marijuana Smokers.

Authors:  Sylvia M Kiertscher; Pallavi R Gangalum; Grace Ibrahim; Donald P Tashkin; Michael D Roth
Journal:  J Neuroimmune Pharmacol       Date:  2018-01-16       Impact factor: 4.147

10.  Association of the interleukin-12 polymorphic variants with the development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients in response to vaccination or infection.

Authors:  Alicja E Grzegorzewska; Piotr M Wobszal; Anna Sowińska; Adrianna Mostowska; Paweł P Jagodziński
Journal:  Mol Biol Rep       Date:  2013-10-25       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.